Mission
Making healthcare advances and innovation immediately accessible to everyone - closer to home - thereby overcoming geographic, social, and economic barriers.
Vision
A world with universal access to health care innovation, where we eliminate death from treatable causes.
Values
-Integrity
-Accountability
-Our Promise to Patients
-Diversity and Inclusion
Who We Are
Cell Therapy Closer to Home
We are a team of experts with over 30 years of experience in hematopoietic stem cell transplantation and cellular therapy.
Together, we can guide your clinic through infrastructure requirements, clinical operations, quality and regulatory compliance.
​
Our passion is making health care innovation accessible to everyone. We want to make cell therapy a reality for everyone who needs it, in the United States and around the world. We believe that no one should die from treatable causes.
​
It is extremely difficult to transform community health care centers into centers that can provide cellular therapy safely. We know how to do it. The only way is having the right expertise.
​​
What we offer is a level and depth of guidance that cannot be acquired overnight, in a week, or even a year. It cannot be replaced by a checklist. Our team has grown and evolved alongside cellular therapy, all the way from hematopoietic transplantation to CAR T-cells.
​
Together, we fully cover all aspects of the expertise you need.
​
Meet the Team
CellServe is comprised of premier researchers and hematologists/oncologists. We are a team with unique, complementary, and synergistic skills honed during years of experience in the field.
Dr. Couriel is an expert in operational organization and quality in all aspects of cellular therapy. He has worked in the Foundation for Accreditation of Cellular Therapy (FACT) for over 20 years and is now on their Board of Directors and chairs the Task Force for New Business Development.
Founder
​
Daniel Couriel, MD, MS, MBA
Chief Executive Officer
​
Alayna Williamson, MBA
Ms. Williamson has over 20 years of leadership and business management experience with expertise in healthcare finance, scaling complex projects and organizations, and providing optimal cancer patient care.
Dr. De Lima has been instrumental in developing and facilitating the manufacturing of CAR T-cells at points of care in the U.S. and globally.
He has been a dedicated clinician, clinical investigator, and leader in the field of Hematopoietic Stem Cell Transplantation (HSCT) for over 30 years.
Chief Medical Officer
​
Marcos De Lima, MD
Dr. Wald pioneers cutting-edge manufacturing technologies in his laboratory, including CAR T-cells and other products that are not only intended to improve outcomes and tolerance of cellular therapy, but to broaden access to these products.
Chief Scientific Officer
​
David Wald, MD, PhD